Shattuck Labs (STTK) Competitors $0.82 +0.04 (+5.32%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.82 +0.01 (+0.67%) As of 07/11/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock STTK vs. NVCT, CGEN, ACRS, BIOA, MOLN, ALEC, VTYX, LXEO, THTX, and BDTXShould you be buying Shattuck Labs stock or one of its competitors? The main competitors of Shattuck Labs include Nuvectis Pharma (NVCT), Compugen (CGEN), Aclaris Therapeutics (ACRS), BioAge Labs (BIOA), Molecular Partners (MOLN), Alector (ALEC), Ventyx Biosciences (VTYX), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Shattuck Labs vs. Its Competitors Nuvectis Pharma Compugen Aclaris Therapeutics BioAge Labs Molecular Partners Alector Ventyx Biosciences Lexeo Therapeutics Theratechnologies Black Diamond Therapeutics Shattuck Labs (NASDAQ:STTK) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership. Do institutionals & insiders hold more shares of STTK or NVCT? 58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 12.0% of Shattuck Labs shares are held by company insiders. Comparatively, 30.5% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is STTK or NVCT more profitable? Shattuck Labs' return on equity of -79.69% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Shattuck LabsN/A -79.69% -69.13% Nuvectis Pharma N/A -148.83%-95.60% Do analysts recommend STTK or NVCT? Shattuck Labs presently has a consensus price target of $7.50, indicating a potential upside of 819.68%. Nuvectis Pharma has a consensus price target of $17.00, indicating a potential upside of 115.74%. Given Shattuck Labs' higher possible upside, research analysts clearly believe Shattuck Labs is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shattuck Labs 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.83Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, STTK or NVCT? Shattuck Labs has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Which has stronger earnings & valuation, STTK or NVCT? Nuvectis Pharma has lower revenue, but higher earnings than Shattuck Labs. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioShattuck Labs$5.72M6.83-$75.41M-$1.39-0.59Nuvectis PharmaN/AN/A-$19M-$1.13-6.97 Does the media refer more to STTK or NVCT? In the previous week, Nuvectis Pharma had 3 more articles in the media than Shattuck Labs. MarketBeat recorded 4 mentions for Nuvectis Pharma and 1 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.89 beat Nuvectis Pharma's score of 1.85 indicating that Shattuck Labs is being referred to more favorably in the media. Company Overall Sentiment Shattuck Labs Very Positive Nuvectis Pharma Very Positive SummaryShattuck Labs beats Nuvectis Pharma on 8 of the 15 factors compared between the two stocks. Get Shattuck Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STTK vs. The Competition Export to ExcelMetricShattuck LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.06M$2.94B$5.55B$9.11BDividend YieldN/A2.42%5.07%4.01%P/E Ratio-0.5920.7128.2120.26Price / Sales6.83292.82432.0099.74Price / CashN/A42.1137.1257.67Price / Book0.497.638.045.49Net Income-$75.41M-$55.05M$3.19B$250.45M7 Day Performance-2.34%8.43%3.63%4.79%1 Month Performance-23.79%5.42%4.06%7.68%1 Year Performance-80.54%2.03%30.02%16.44% Shattuck Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STTKShattuck Labs3.7164 of 5 stars$0.82+5.3%$7.50+819.7%-79.9%$39.06M$5.72M-0.59100Positive NewsHigh Trading VolumeNVCTNuvectis Pharma3.3682 of 5 stars$7.85+4.1%$17.00+116.6%+23.1%$157.54MN/A-6.958Positive NewsCGENCompugen1.7828 of 5 stars$1.72-2.3%$4.00+132.6%-9.1%$157.06M$27.86M-10.7570Positive NewsACRSAclaris Therapeutics2.2385 of 5 stars$1.46+1.4%$9.71+565.4%+24.6%$155.93M$18.72M-1.05100Analyst ForecastBIOABioAge LabsN/A$4.18-2.3%N/AN/A$153.44MN/A0.00N/AMOLNMolecular Partners3.1252 of 5 stars$3.61-4.0%$12.00+232.4%-47.1%$151.81M$2.23M-1.88180ALECAlector3.9927 of 5 stars$1.44-4.6%$4.00+177.8%-70.2%$150.99M$100.56M-1.14270News CoverageVTYXVentyx Biosciences3.5109 of 5 stars$2.04-1.9%$10.00+390.2%+10.9%$148.01MN/A-1.1730News CoverageLXEOLexeo Therapeutics2.3632 of 5 stars$4.54+2.0%$16.60+265.6%-74.4%$147.73M$650K-1.3858Gap UpHigh Trading VolumeTHTXTheratechnologiesN/A$3.17-0.9%N/A+117.2%$147.14M$85.87M-39.63140Positive NewsEarnings ReportHigh Trading VolumeBDTXBlack Diamond Therapeutics2.7692 of 5 stars$2.50-3.1%$12.80+412.0%-46.8%$146.71MN/A41.6790News CoveragePositive News Related Companies and Tools Related Companies Nuvectis Pharma Competitors Compugen Competitors Aclaris Therapeutics Competitors BioAge Labs Competitors Molecular Partners Competitors Alector Competitors Ventyx Biosciences Competitors Lexeo Therapeutics Competitors Theratechnologies Competitors Black Diamond Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STTK) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shattuck Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shattuck Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
